BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

726 related articles for article (PubMed ID: 32245497)

  • 1. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy.
    Pan C; Liu H; Robins E; Song W; Liu D; Li Z; Zheng L
    J Hematol Oncol; 2020 Apr; 13(1):29. PubMed ID: 32245497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing.
    Li Z; Song W; Rubinstein M; Liu D
    J Hematol Oncol; 2018 Dec; 11(1):142. PubMed ID: 30577797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Challenges of Immune Checkpoint Inhibitors.
    de Miguel M; Calvo E
    Cancer Cell; 2020 Sep; 38(3):326-333. PubMed ID: 32750319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized Immuno-Oncology.
    Jain KK
    Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalization Cancer Immunotherapy for Melanoma.
    Vesely MD; Chen L
    J Invest Dermatol; 2020 Jun; 140(6):1134-1142. PubMed ID: 32092349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
    Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
    Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
    Wong RL; Yu EY
    Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.
    Kumar AR; Devan AR; Nair B; Vinod BS; Nath LR
    Mol Biol Rep; 2021 Dec; 48(12):8075-8095. PubMed ID: 34671902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy.
    Sun J; Lu Q; Sanmamed MF; Wang J
    Clin Cancer Res; 2021 Feb; 27(3):680-688. PubMed ID: 32958700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.
    Liberini V; Laudicella R; Capozza M; Huellner MW; Burger IA; Baldari S; Terreno E; Deandreis D
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33920423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Immunotherapy - The Target is Precisely on The Cancer and Also Not.
    Koo SL; Wang WW; Toh HC
    Ann Acad Med Singap; 2018 Sep; 47(9):381-387. PubMed ID: 30324966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
    Ayala-Mar S; Donoso-Quezada J; González-Valdez J
    J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
    Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
    J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence.
    Huemer F; Leisch M; Geisberger R; Melchardt T; Rinnerthaler G; Zaborsky N; Greil R
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade.
    Wilkinson RW; Leishman AJ
    Front Immunol; 2018; 9():1082. PubMed ID: 29910800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
    Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
    J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.